Overview

Temsirolimus as Second-line Therapy in HCC

Status:
Unknown status

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the activity of temsirolimus in patients who have advanced hepatocellular carcinoma (HCC) and have been treated with one previous chemotherapy or biologic therapy like sorafenib, but have experienced disease progression or intolerance to that therapy.

Phase:

Phase 2

Details

Lead Sponsor:

University of Tennessee Cancer Institute

Collaborator:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Everolimus
Sirolimus